Answers are grounded in this paper and cite their sources.
Longitudinal data reveal factors linked to healthcare utilization in inflammatory bowel disease, suggesting proactive risk assessment can improve management.
Background Remote monitoring in IBD may help identify patients at risk of higher healthcare use. The TrueColours-IBD (TC-IBD) system, initiated at the Oxford University Hospitals in 2018, enables patients to report baseline case mix variables, weekly symptoms (HBI for CD; SCCAI for UC), fortnightly health-related quality of life (HRQoL - derived from the EQ-5D), and three-monthly healthcare use (ICHOM). We identified factors associated with hospitalisation, emergency department (ED) admission, and related costs using the longitudinal TC-IBD data. Methods Adults with IBD enrolled in TC-IBD (June 2018–Feb 2025) and ≥6 months of follow-up were included. Data were aggregated into 3-month panels using the most severe values within each period, and 3-month lagged variables to ensure temporal ordering. Random-effects logistic regression examined associations between HBI, SCCAI and EQ-5D scores, and subsequent hospitalisation or ED visits, adjusting for demographic and clinical covariates. Annual costs were calculated using reported hospital use and unit costs, and population-level costs estimated by applying average per-patient event rates to the UK IBD population. Analyses were performed in Stata 19. Results By Feb 2025, 3,197 patients were included (59.8% UC, 40.2% CD; median [IQR] age 45.5 [34.5–59.4] years and disease duration 4,000 [1,999–7,277] days), contributed 48,732 observations, with per patient a mean of 3.41 (SD 1.10) time periods per year and 15.2 in total. A total of 836 hospitalisations and 1,182 ED visits occurred among 501 and 672 patients respectively. Higher odds of hospitalisation and ED visits were associated with EQ-5D pain/discomfort and limitations in usual activities, HBI and SCCAI total and general wellbeing scores, and SCCAI-reported blood in stool. Worse overall HRQoL was associated with increased ED use, while impaired self-care and overall health, higher HBI liquid stools and SCCAI bowel frequency were associated with hospitalisations (Table 1). Estimated annual costs for the full UK IBD population were £111,234,917 for hospitalisations and £13,089,422 for ED admissions (Table 2). Conclusion This large longitudinal patient-reported dataset allowed to identify key factors - including general wellbeing and pain/discomfort in addition to total scores - associated with hospital and ED use, highlighting their potential for targeted real-time risk stratification, and enabled estimation of related costs. Integrating remote monitoring into routine care may help enable proactive and cost-effective IBD management. References: (1) Walsh A, Matini L, Hinds C, Sexton V, Brain O, Keshav S, et al. Real-time data monitoring for ulcerative colitis: patient perception and qualitative analysis. Intest Res. 2019 Jul 30;17(3):365–74. (2)NHS 2022/23 National Cost Collection Data Publication. https://www.england.nhs.uk/publication/2022-23-national-cost-collection-data-publication-2/. Accessed 17 Nov 2025. (3) Nartey Y, Ratna M, Card TR, et al. Incidence and prevalence of inflammatory bowel disease across the United Kingdom.University of Nottingham. 2021. https://www.crohnsandcolitis.org.uk/media/pkamxda4/uonreport2021_ibd_incidandprev.pdf. Accessed 17 Nov 2025. Conflict of interest: Mrs. Fierens, Liselotte: No conflict of interest Clarke, Philip: No conflict of interest Dunbar, Grace: No conflict of interest Kormilitzin, Andrey: I hold research grants from: - the National Institute for Health and Care Research (UK) - GlaxoSmithKline - Pfizer - Alzheimer’s Research UK Matini, Lawrence: Speaker fees: AbbVie, Galapagos, Bristol Myers Squibb Punj Sharda, Anita: No conflict of interest Travis, Simon: Research Support: AbbVie, Celgene, Celsius, ECCO, Galapagos, GSK, Helmsley Trust, IOIBD, Janssen, Lilly, Pfizer, Takeda, UKIERI, 35Bio, Vifor, and Norman Collisson Foundation Consulting Fees: Alimentiv Apexian Apollo Arcturis AstraZeneca BMS Clario Cosmo Dova Health Endpoint Health EQrX Equillium Ferring Galapagos Genentech/Roche Gilead GSK Janssen Iterative Health Lilly Mestag Microbiotica ONO Pfizer Phesi Protagonist Sanofi Satisfai Sensyne Health Spyre Takeda Teva Theravance Tr1X Bio Speaker fees: BMS, Ferring, GSK, Janssen, Lilly, Pfizer, Sun Pharma, Takeda. Share options: Dova Health Inc. Walsh, Alissa: Grant: Alfasigma, Helmsley Trust, Johnson & Johnson, Pfizer, Takeda Personal Fees: AbbVie, Alfasigma, Bristol Meyers Squibb, Dr Falk, Ferring, Johnson & Johnson, Lilly, Pfizer, Takeda, Tillotts Violato, Mara: No conflicts
No takes yet. Share an insight, caveat, or question.
Fierens et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: